ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
At the 11th Berlin Conference, Novo Holdings outlined details of a new €135m investment fund launched to push the development of new drug classes urgently needed to fight antimicrobial resistance. European Biotechnology editors were the first to talk with Aleks Engel, Partner at Novo Holdings, and George Griffin, Chair of the Repair Impact Fund’s Scientific Advisory Board, about the construction and the goal of the fund.
Researchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist variation in histopathological diagnosis and resulted in a change of diagnoses in up to 12% of prospective cases.
The tremendous success of last year’s BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised as a worthy successor.
German MYR Pharma has completed a proof of concept Phase IIb trial with its first-in-class hepatitis D entry inhibitor Myrcludex B, which is developed under the European Medicines Agency’s PRIME scheme.
Alirocumab, Sanofi’ s/Regeneron’s PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy in 18,924 high-risk patients.
Researchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis.
The adage you are what you eat’ is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. It’s now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.
Evotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofi’s antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agreement.
Personalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018.